- You can view the full Biomarin Pharmaceutical Ratings Report.
- Use our drugs section to find industry-relevant news.
- Or find some new ideas from our top rated stocks lists.
- Find other investment ideas from our top rated ETFs lists.
Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link. Biomarin Pharmaceutical ( BMRN) pushed the Drugs industry higher today making it today's featured drugs winner. The industry as a whole closed the day up 1.1%. By the end of trading, Biomarin Pharmaceutical rose $1.34 (1.9%) to $70.80 on heavy volume. Throughout the day, 1,558,983 shares of Biomarin Pharmaceutical exchanged hands as compared to its average daily volume of 1,016,000 shares. The stock ranged in a price between $69.48-$70.85 after having opened the day at $69.55 as compared to the previous trading day's close of $69.46. Other companies within the Drugs industry that increased today were: GW Pharmaceuticals PLC ADR ( GWPH), up 89.3%, Rockwell Medical ( RMTI), up 32.5%, Echo Therapeutics ( ECTE), up 12.9% and Portola Pharmaceuticals ( PTLA), up 12.6%. BioMarin Pharmaceutical Inc. develops and commercializes biopharmaceuticals for serious diseases and medical conditions in the United States, Europe, Latin America, and internationally. Biomarin Pharmaceutical has a market cap of $9.5 billion and is part of the health care sector. Shares are up 41.2% year to date as of the close of trading on Wednesday. Currently there are 12 analysts that rate Biomarin Pharmaceutical a buy, no analysts rate it a sell, and 3 rate it a hold. TheStreet Ratings rates Biomarin Pharmaceutical as a hold. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures and solid stock price performance. However, as a counter to these strengths, we also find weaknesses including weak operating cash flow and feeble growth in the company's earnings per share.
